Pale Fire Capital SE Boosts Stock Holdings in Mineralys Therapeutics, Inc. $MLYS

Pale Fire Capital SE grew its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 3,431.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 365,626 shares of the company’s stock after purchasing an additional 355,272 shares during the period. Mineralys Therapeutics makes up about 0.8% of Pale Fire Capital SE’s holdings, making the stock its 16th biggest position. Pale Fire Capital SE’s holdings in Mineralys Therapeutics were worth $9,905,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC increased its stake in Mineralys Therapeutics by 130.7% in the 4th quarter. SG Americas Securities LLC now owns 230,795 shares of the company’s stock worth $8,376,000 after acquiring an additional 130,758 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Mineralys Therapeutics by 234.4% during the 4th quarter. Jennison Associates LLC now owns 1,258,653 shares of the company’s stock valued at $45,677,000 after acquiring an additional 882,307 shares during the last quarter. TimesSquare Capital Management LLC bought a new stake in shares of Mineralys Therapeutics during the 4th quarter valued at about $13,794,000. UBS Group AG grew its holdings in shares of Mineralys Therapeutics by 124.9% during the fourth quarter. UBS Group AG now owns 201,280 shares of the company’s stock worth $7,304,000 after purchasing an additional 111,776 shares in the last quarter. Finally, Profund Advisors LLC grew its holdings in shares of Mineralys Therapeutics by 548.1% during the fourth quarter. Profund Advisors LLC now owns 47,024 shares of the company’s stock worth $1,707,000 after purchasing an additional 39,768 shares in the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MLYS has been the topic of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Wall Street Zen cut shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. TD Cowen began coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They set a “buy” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.33.

Mineralys Therapeutics Trading Down 1.1%

Shares of Mineralys Therapeutics stock opened at $26.71 on Friday. The firm has a market capitalization of $2.20 billion, a PE ratio of -13.03 and a beta of 0.66. The business’s 50-day moving average price is $27.05 and its 200-day moving average price is $28.24. Mineralys Therapeutics, Inc. has a 12 month low of $12.59 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.04. As a group, analysts predict that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the transaction, the chief executive officer owned 614,321 shares in the company, valued at $16,058,350.94. This trade represents a 10.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of Mineralys Therapeutics stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.90, for a total transaction of $2,696,811.60. Following the completion of the transaction, the insider owned 38,400 shares in the company, valued at approximately $994,560. The trade was a 73.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 230,280 shares of company stock valued at $6,018,442 over the last ninety days. Insiders own 18.94% of the company’s stock.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.